News

Merck's Verona Acquisition: Plugging A $4B Hole In A $20B Gap
Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...
Dealbreaker on MSN2d
Merck Breathes Life Into Its Respiratory Prospects With $10B Deal to Buy Verona Pharma
Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive ...
BioPharma Dive2d
With Verona deal, Merck wagers on strength of lung drug’s patents
The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...
Merck shells out $10 billion for Verona in bid to diversify beyond Keytruda
Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...
Raleigh pharma's $10B sale pays off for Boston, NY investment firms
Investment firms in Boston and New York could see the biggest gains from the sale of a Raleigh drugmaker. Raleigh firm rides ...
Merck Acquires Verona Pharma for $10B to Support Portfolio with COPD Drug Ohtuvayre Ahead of Keytruda Patent Expiration
Merck & Co. Inc. (NYSE:MRK) is one of the most undervalued NYSE stocks to buy now. On July 9, Merck announced its acquisition ...
These Stocks Are Moving the Most Today: Nvidia, AES, Verona Pharma, WPP, Bloom Energy, Aehr Test Systems, and More
Stocks traded higher Wednesday as Wall Street focused on the latest tariff developments from President Donald Trump and ...
STAT4d
Pharmalittle: We’re reading about Trump’s latest tariff threat, a Merck deal, and lots more
President Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S., but not immediately ...